Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

SourceYahoo Finance
Date Published10/31/2022
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Paratek Pharmaceuticals
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2023
Domestically, the work will be done:In-house
Capital investment ($):304
City reshored to:Boston
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredNUZYRA antibiotic
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Government Incentives, Impact on domestic economy, BARDA
Government Incentive dollar amount:$304 million BARDA contract
Find Reshoring Articles